Kura Oncology has presented promising preliminary data from the FIT-001 clinical trial, evaluating the combination of darlifarnib and cabozantinib in patients with clear cell renal cell carcinoma (ccRCC) who have previously been treated with cabozantinib. This subset analysis revealed a 44% objective response rate (ORR) and an impressive 94% disease control rate (DCR) among a heavily pretreated population, with tumor shrinkage observed in 75% of these patients. Notably, responses were documented even in individuals whose best prior response to cabozantinib was stable disease, indicating a potential for resensitization to VEGF TKI therapy.

The significance of these findings lies in the ability of darlifarnib to overcome resistance mechanisms typically associated with cabozantinib treatment. As patients who progress on cabozantinib often face limited therapeutic options, the durable treatment durations of up to 56 weeks and the manageable safety profile across multiple dosing regimens underscore the potential of this combination strategy. Previous data presented at the 2025 ESMO conference also support darlifarnib’s role in enhancing the efficacy of VEGFR-targeted therapies, aligning with the current trial’s outcomes.

The implications for the field are substantial, as these results may shift the paradigm for treating advanced ccRCC patients who have exhausted standard therapies. By demonstrating that darlifarnib can effectively resensitize tumors to VEGF TKIs, this combination could accelerate drug development timelines and inform future clinical strategies aimed at addressing treatment resistance in renal cell carcinoma. As the FIT-001 study advances into Phase 1b dose expansion, the findings could pave the way for innovative therapeutic approaches in oncology.

Source: globenewswire.com